Abstract: A method for determining a consistency coefficient of a power-law cement grout includes: determining a water-cement ratio of the power-law cement grout; according to engineering practice requirements, determining a time required to determine the consistency coefficient of the power-law cement grout; and obtaining the consistency coefficient of the power-law cement grout. The method is accurate and reliable, requires less calculation, etc.; and has very high practical value and popularization value in environmental protection and ecological restoration.

Abstract: A pharmacological composition contains a complex having a structurally modified RGD polypeptide a radionuclide. This pharmacological composition is useful for diagnosis or treatment of the integrin ?v?3-positive tumors. The pharmacological composition may further contain an immunotherapeutic medicament and an optional nanoantibody molecular imaging probe. Treatment with a PD-L1 blockade after the targeted radioactive therapy can archive the optimal synergic efficacy. Moreover, with administration of PD-1 or PD-L1 nanoantibody molecular imaging probe, expression of PD-1 or PD-L1 in the tumor after targeted radiotherapy can be observed.

Abstract: Disclosed are an rk polypeptide radiopharmaceutical targeting HER2, and a preparation method therefor. The rk polypeptide radiopharmaceutical comprises an rk polypeptide dimer and a radionuclide, wherein the radionuclide marks the rk polypeptide dimer by means of a chelating agent, the rk polypeptide dimer is a polypeptide dimer formed by connecting PKM and rk polypeptide monomers and then dimerizing two rk polypeptide monomers connected to the PKM; each rk polypeptide monomer is a D-type amino acid linear eight-membered polypeptide, and the sequence of the rk polypeptide monomer is as follows: Arg-Asn-Trp-Glu-Leu-Arg-Leu-Lys; and the PKM represents a pharmacokinetic modifying molecule. The radiopharmaceutical is used for imaging diagnosis of HER2-positive tumor patients, and medication guidance and real-time therapeutic effect monitoring of patients treated by monoclonal antibodies of the anti-cancer drug trastuzumab.

Abstract: The present invention is related to computer-assisted process design, and an MBD-based three-dimensional process designing method and platform for a typical automobile machined part are disclosed. By taking three-dimensional CAD software as a carrier, an MBD design model, and a process MBD model as a data output, the design flow comprises steps such as establishment of MBD-related standards, creation of an MBD design model, feature classification and creation of a feature library, feature recognition and information extraction, generation of manufacturing elements, clustering of the manufacturing elements and generation of procedures, sequencing of the procedures, and creation of manufacturing features body and procedure models.

Abstract: The present invention is related to computer-assisted process design, and an MBD-based three-dimensional process designing method and platform for a typical automobile machined part are disclosed. By taking three-dimensional CAD software as a carrier, an MBD design model, and a process MBD model as a data output, the design flow comprises steps such as establishment of MBD-related standards, creation of an MBD design model, feature classification and creation of a feature library, feature recognition and information extraction, generation of manufacturing elements, clustering of the manufacturing elements and generation of procedures, sequencing of the procedures, and creation of manufacturing features body and procedure models.

Abstract: The present invention relates to a method and a network node for selecting transmission mode to a cell providing Multicasting/Broadcasting Multimedia Service, MBMS, which cell is served by the network node in a MBMS single frequency network and comprising at least one user equipment receiving or requesting MBMS data. The network node obtains (601) a first parameter related to a quality of the MBMS experienced by the at least one user equipment and compares Based the first parameter with a predefined first threshold value. Based on the result of comparison the network node selects (604) a transmission mode to the cell.

Abstract: The present invention relates to a method and a network node for selecting transmission mode to a cell providing Multicasting/Broadcasting Multimedia Service, MBMS, which cell is served by the network node in a MBMS single frequency network and comprising at least one user equipment receiving or requesting MBMS data. The network node obtains (601) a first parameter related to a quality of the MBMS experienced by the at least one user equipment and compares Based the first parameter with a predefined first threshold value. Based on the result of comparison the network node selects (604) a transmission mode to the cell.